GLP1R and Parkinson disease: Similarly, the glucagon-like 1 peptide receptor agonist, NYL01, originally developed to combat inflammation in diabetes, has proved beneficial in limiting microglia cytokine release and astrocyte reactivity in mouse models of PD [74], as well as in the bead-occlusion model of glaucoma [75].